secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001724521-25-000039
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q4 2024 net loss $94M; casdatifan shows best-in-class potential in ccRCC
------------------------------------------------------------------------------

- Revenue $36M for Q4 2024 ($31M Q4 2023); net loss widened to $94M from $81M.
- Cash & marketable securities $992M as of Dec 31, 2024, up from $866M year-end 2023.
- Casdatifan monotherapy in IO/VEGFR-TKI experienced ccRCC achieved 30%+ ORR, 9.7-month median PFS (50mg BID).
- Phase 3 PEAK-1 (casdatifan + cabozantinib vs cabo in post-IO ccRCC) expected to initiate Q2 2025.
- Domvanalimab/zimberelimab Phase 3 STAR-221 top-line data for 1L upper GI cancers expected 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000039/0001724521-25-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000039/rcus-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer